0000000000248003

AUTHOR

Marco Davì

showing 7 related works from this author

Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach

2021

Abstract Introduction Essential Tremor (ET) is increasingly recognized as a complex disorder with additional clinical signs other than tremor. It is still unknown whether a unique pathophysiologic or neurodegenerative process underlies progression and prognosis of the disease. The aim of the study was to identify ET phenotypes through a clinical-instrumental data-driven approach and to characterize possible patterns of neurodegeneration. Methods ET patients were categorized using spatio-temporal and kinematic variables related to mobility and dynamic stability processed by motion transducers. Differences between the identified groups in clinical-demographic variables, neuropsychological per…

0301 basic medicineRetinal degenerationMalemedicine.medical_specialtyHead tremorTimed up and go testRetina03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitation80 and overNeurologicMedicineHumansCognitive DysfunctionGait DisordersCognitive declineNeurodegenerationTomographyGait Disorders NeurologicAgedAged 80 and overEssential tremorOptical coherence tomographybusiness.industryNeuropsychologyCognitionNeurodegenerative Diseasesmedicine.diseaseAction tremorGait030104 developmental biologyNeurologyOptical CoherenceEssential tremorFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeurology (clinical)Geriatrics and Gerontologybusiness030217 neurology & neurosurgeryTomography Optical Coherence
researchProduct

Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort

2021

AbstractAim of the study was to evaluate possible associations between cognitive dysfunctions and development of Levodopa Induced Dyskinesia (LID). PD patients from the Parkinson’s disease Cognitive impairment Study cohort who underwent a baseline and follow-up neuropsychological evaluations were enrolled. Mild Cognitive Impairment (PD-MCI) was diagnosed according to MDS level II criteria. The following cognitive domains were evaluated: episodic memory, attention, executive function, visuo-spatial function and language. A domain was considered as impaired when the subject scored 2 standard deviation below normality cut-off values in at least one test for each domain. Levodopa equivalent dos…

Male0301 basic medicineDyskinesia Drug-InducedLevodopamedicine.medical_specialtyParkinson's diseaseScienceNeuropsychological TestsSeverity of Illness IndexArticleCohort StudiesLevodopaExecutive Function03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansAttentionCognitive DysfunctionLongitudinal StudiesAgedProportional Hazards ModelsLevodopa-induced dyskinesiaMultidisciplinarybusiness.industryQRNeuropsychologyParkinson DiseaseCognitionMiddle Agedmedicine.diseaseAged Attention Cognitive Dysfunction Cohort Studies Dyskinesia Drug-Induced Executive Function Female Humans Levodopa Longitudinal Studies Male Middle Aged Neuropsychological Tests Parkinson Disease Proportional Hazards Models Severity of Illness Index030104 developmental biologyNeurologyRisk factorsDyskinesiaCohortMedicineFemalemedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugCohort studyScientific Reports
researchProduct

Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS)

2018

Approximately 30% of Parkinson's disease (PD) patients show impaired cognitive performance, which is suggestive of Mild Cognitive Impairment (MCI), representing a predictor of dementia, especially when present at diagnosis. The objective of the study was to evaluate the frequency and clinical predictors of MCI in a large hospital-based cohort of PD patients. We collected cross-sectional data from the Parkinson's disease cognitive impairment study (PACOS), a multicenter study involving two Movement Disorder centers, which are located in south Italy. The PD subjects were diagnosed according to the UK Brain Bank criteria and they underwent an extensive neuropsychological assessment. PD-MCI was…

Male0301 basic medicinemedicine.medical_specialtyNeurologyParkinson's diseaseEpidemiologyParkinson's diseaseNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyOdds RatioPrevalenceHumansMedicineDementiaCognitive DysfunctionParkinsonâ s diseaseEffects of sleep deprivation on cognitive performanceNeuropsychological assessmentAge of OnsetCognitive impairment; Epidemiology; Parkinson’s disease; Prevalence; Neurology; Neurology (clinical)AgedRetrospective Studiesmedicine.diagnostic_testbusiness.industryParkinson Diseasemedicine.diseasenervous system diseasesCross-Sectional StudiesCognitive impairment030104 developmental biologyNeurologyMultivariate AnalysisCohortEducational StatusSettore MED/26 - NeurologiaFemaleAmnesiaNeurology (clinical)businesshuman activities030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study.

2018

Background: Cognitive impairment in Parkinson's disease (PD) includes a spectrum varying from Mild Cognitive Impairment (PD-MCI) to PD Dementia (PDD). The main aim of the present study is to evaluate the incidence of PD-MCI, its rate of progression to dementia, and to identify demographic and clinical characteristics which predict cognitive impairment in PD patients. Methods: PD patients from a large hospital-based cohort who underwent at least two comprehensive neuropsychological evaluations were retrospectively enrolled in the study. PD-MCI and PDD were diagnosed according to the Movement Disorder Society criteria. Incidence rates of PD-MCI and PDD were estimated. Clinical and demographic…

0301 basic medicineAgingmedicine.medical_specialtyParkinson's diseaseCognitive NeuroscienceParkinson's diseasebehavioral disciplines and activitieslcsh:RC321-57103 medical and health sciences0302 clinical medicinemild cognitive impairmentInternal medicinemental disordersMedicineDementiaNeuropsychological assessmentMild cognitive impairment (MCI)lcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchmedicine.diagnostic_testbusiness.industryProportional hazards modelIncidence (epidemiology)Neuropsychologymedicine.diseasenervous system diseasesneuropsychological assessment030104 developmental biologyCohortParkinson’s diseaseincidencebusiness030217 neurology & neurosurgeryNeurosciencedementiaFrontiers in aging neuroscience
researchProduct

Cardiovascular autonomic function and MCI in Parkinson's disease

2019

Abstract Introduction dysautonomic dysfunction and cognitive impairment represent the most disabling non-motor features of Parkinson's Disease (PD). Recent evidences suggest the association between Orthostatic Hypotension (OH) and PD-Dementia. However, little is known on the interactions between cardiovascular dysautonomia and Mild Cognitive Impairment (MCI). We aimed to evaluate the association between cardiovascular dysautonomia and MCI in patients with PD. Methods non-demented PD patients belonging to the PACOS cohort underwent a comprehensive instrumental neurovegetative assessment including the study of both parasympathetic and sympathetic function (30:15 ratio, Expiratory-Inspiratory …

Male0301 basic medicineAutonomic functionmedicine.medical_specialtyAutonomic systemParkinson's diseaseParkinson's diseasePrimary DysautonomiasDiseaseHypotension Orthostatic03 medical and health sciencesOrthostatic vital signs0302 clinical medicineInternal medicineHumansMedicineCognitive DysfunctionCognitive impairmentAgedRetrospective Studiesbusiness.industryMild cognitive impairmentDysautonomiaParkinson DiseaseMiddle Agedmedicine.disease030104 developmental biologyNeurologyCohortCardiologyFemaleCardiovascular dysautonomiaNeurology (clinical)Level iiGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Morphometric magnetic resonance imaging cortico-subcortical features in Parkinson's disease with mild cognitive impairment

2022

Background and purpose Parkinson's disease (PD) patients with cognitive impairment undergo progressive atrophy of several cortical and subcortical areas. The aim was to study the magnetic resonance imaging (MRI) morphometric features of PD patients with mild cognitive impairment (MCI). Methods Patients from the Parkinson's Disease Cognitive Impairment Study (PACOS) cohort with an available structural volumetric brain MRI and morphometric measurements of the midbrain and pons areas, middle cerebellar peduncle, superior cerebellar peduncle width and midbrain anteroposterior diameter (A-Pdiam) were included. MCI was diagnosed according to the Movement Disorder Society level II criteria. Additi…

Cerebral CortexMaleParkinson's diseaseParkinson DiseasemidbrainNeuropsychological TestsbrainstemNeurologyParkinson’s diseaseHumansmagnetic resonance imagingCognitive DysfunctionFemaleSettore MED/26 - NeurologiaNeurology (clinical)Atrophycognitive impairment
researchProduct

Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study

2020

Abstract Background Vascular risk factors (VRFs) may be associated with cognitive decline in early Parkinson’s disease (PD) but results are inconclusive. The identification of modifiable risk factors is relevant for prevention and treatment. Methods Parkinson’s disease (PD) patients of the PACOS cohort who underwent a baseline and follow-up neuropsychological evaluation were enrolled in the study. PD with Mild Cognitive Impairment (MCI) and dementia (PDD) were diagnosed according to the MDS criteria. A Baseline 1.5 T brain MRI was used to calculate the white matter lesions (WMLs) burden using the Wahlund visual scale. Laboratory data, presence of hypertension, diabetes and use of anti-hyper…

0301 basic medicinemedicine.medical_specialtyEpidemiologyNeuropsychological Testsbehavioral disciplines and activitiesWhite matter lesions03 medical and health sciences0302 clinical medicineInternal medicinemental disordersEpidemiologyHumansMedicineDementiaCognitive DysfunctionLongitudinal StudiesRisk factorCognitive declineOriginal CommunicationFramingham Risk Scorebusiness.industryMild cognitive impairmentParkinson DiseaseEpidemiology Hypertension Mild cognitive impairment Parkinson’s disease Risk factors White matter lesions Humans Longitudinal Studies Neuropsychological Tests Risk Factors Cognitive Dysfunction Parkinson Disease White Mattermedicine.diseaseWhite MatterHyperintensitynervous system diseases030104 developmental biologyBlood pressureRisk factorsNeurologyHypertensionCohortParkinson’s diseaseNeurology (clinical)business030217 neurology & neurosurgeryJournal of Neurology
researchProduct